Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
11/2009
11/03/2009US7612088 Heterocyclic compounds and their use as aldosterone synthase inhibitors
11/03/2009US7612087 Heterocyclic compounds as inhibitors of beta-lactamases
11/03/2009US7612086 Jun N-terminal kinase inhibitors; 1H-pyrrolo[2,3-b]pyridines 3-substituted with a C 5-7 carbocycle and 5-substituted by a 5-member heterocycle; 3-(p-(dimethylamino)phenyl)-5-(2-thiazolyl-1H-pyrrolo[2,3-b]pyridine; neurodegenerative disorders related to apoptosis and/or inflammation
11/03/2009US7612083 Urea substituted imidazoquinoline ethers
11/03/2009US7612075 Anticaogulants; cardiovascular disorders
11/03/2009US7612070 Indole derivative having heterocycle and mono- or diazaindole derivative
11/03/2009US7612063 antibiotics, fungicides, viricides; treating microbial infections; fused rings based on 4-oxo-4H-pyrido[3,2,1-kl]benzo[g]-phenoxazine for example; Tumor suppression agents with reduced side effects; anticancer
11/03/2009US7612056 Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
11/03/2009US7612055 Macrocyclic lactams and pharmaceutical use thereof
11/03/2009CA2420579C Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine
11/03/2009CA2409926C Praziquantel compounds for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
11/03/2009CA2360767C Tricyclic benzodiazepines as vasopressin receptor antagonists
10/2009
10/29/2009WO2009132136A1 Carboxamide compounds for the treatment of metabolic disorders
10/29/2009WO2009131973A1 Quinolone derivatives useful as antibacterial agents
10/29/2009WO2009131687A2 Inhibitors of protein kinases
10/29/2009WO2009131096A1 Compound having npy y5 receptor antagonist activity
10/29/2009WO2009131065A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009WO2009130710A2 A process for the preparation of paliperidone intermediates
10/29/2009WO2009130487A1 Aryl-quinolyl compounds and their use
10/29/2009WO2009130469A1 Dna-pk inhibitors
10/29/2009WO2009130223A1 Threefold and fourfold substituted pentarylene tetracarboxylic acid diimides
10/29/2009WO2009130015A1 Improved raf inhibitors
10/29/2009WO2009129625A1 Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
10/29/2009WO2009109782A3 Polycyclic organic compounds, retardation layer and compensation panel based thereon
10/29/2009WO2009109781A3 Polycyclic organic compounds, polarizing elements and method of production thereof
10/29/2009WO2009084024A3 A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
10/29/2009WO2009044413A3 Improved process for preparing paliperidone, novel polymorphic forms of the same and process thereof
10/29/2009WO2008142528A9 An improved process for preparing nevirapine
10/29/2009US20090270626 Stable bisthiol compounds for radioimaging and therapy
10/29/2009US20090270625 Fused quinoline derivative and use thereof
10/29/2009US20090270620 Processes for preparing crystal forms of 9-hydroxy-risperidone (paliperidone)
10/29/2009US20090270593 Nucleic acid binding substance containing catalytic nucleation nanoparticles
10/29/2009US20090270447 2-Aryl-and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof
10/29/2009US20090270444 1,7-Naphthyridines
10/29/2009US20090270443 1-amino imidazo-containing compounds and methods
10/29/2009US20090270442 Polymorphs of hydrochloride salt of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
10/29/2009US20090270440 Bioavailability of active substances having an amidine function in medicaments
10/29/2009US20090270432 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5-AMINE
10/29/2009US20090270431 Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
10/29/2009US20090270430 Pyridopyrimidinone Inhibitors of Pl3Kalpha
10/29/2009US20090270412 Pyrido[3,4-b]indoles and methods of use
10/29/2009US20090270389 Pyrimidinyl pyridone inhibitors of kinases
10/29/2009US20090270388 Fused azole-pyrimidine derivatives
10/29/2009US20090270376 Heterocyclic janus kinase 3 inhibitors
10/29/2009US20090270375 Spiro antibiotic derivatives
10/29/2009US20090270370 Fused heterocyclic compounds
10/29/2009US20090270369 Bicycloamine derivatives
10/29/2009US20090270365 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics
10/29/2009CA2723185A1 Inhibitors of protein kinases
10/29/2009CA2722139A1 Carboxamide compounds for the treatment of metabolic disorders
10/29/2009CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009CA2722020A1 Improved raf inhibitors
10/29/2009CA2721576A1 Compound having npy y5 receptor antagonist activity
10/29/2009CA2721575A1 Aryl-quinolyl compounds and their use
10/29/2009CA2720654A1 Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
10/28/2009EP2112150A1 Improved raf inhibitors
10/28/2009EP1745052B9 Hiv integrase inhibitors: cyclic pyrimidinone compounds
10/28/2009CN101568541A Spirocyclic azaadamantane derivatives and methods of use
10/28/2009CN101568540A Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
10/28/2009CN101568535A Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
10/28/2009CN101568530A Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
10/28/2009CN101568529A Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
10/28/2009CN101568527A 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
10/28/2009CN101567425A Organic electroluminescence device, novel platinum complex compound and novel compound capable of being a ligand thereof
10/28/2009CN100554268C Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
10/27/2009US7608726 Substituted indolepyridinium as anti-infective compounds
10/27/2009US7608717 3-[2-(dimethylamino)ethyl]-1-[(3-fluorophenyl)sulfonyl]-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one; anxiety disorder or a cognitive disorder; central nervous system disorders; psychological disorders; neurodegenerative disorder; attention deficit disorder; obsessive compulsive disorder; Alzheimer's
10/27/2009US7608716 Pyrazolonaphthyridine derivative
10/27/2009US7608712 Pyridine imidazoles and aza-indoles as progesterone receptor modulators
10/27/2009US7608631 1-(4-{3-[2,6-Dichloro-4-(3,3-dichloro-allyloxy)-phenoxy]-propoxy}-phenyl)-1H-pyrrole, for example; protecting soybean plants against pests such as caterpillars
10/27/2009US7608627 6-azaindole compound
10/27/2009US7608622 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one;
10/27/2009CA2494234C Methods and dosage forms for controlled delivery of paliperidone
10/27/2009CA2465534C Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
10/27/2009CA2437006C Aminotriazolopyridine derivatives as adenosine receptor ligands
10/27/2009CA2381885C Isomeric fused pyrrolocarbazoles and isoindolones
10/27/2009CA2322171C Cyclic amino compounds
10/27/2009CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
10/22/2009WO2009129401A1 Kinase inhibitors
10/22/2009WO2009129259A2 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
10/22/2009WO2009129191A1 Polymorphs of hydrochloride salt o5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b] indole-7-carboxamideand methods of use therefor
10/22/2009WO2009127949A1 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
10/22/2009WO2009127609A1 Spirocyclic derivatives as histone deacetylase inhibitors
10/22/2009WO2009106745A3 Method for enantio-selective preparation of sulphoxides
10/22/2009WO2008032162A8 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
10/22/2009US20090264653 Useful indole compounds
10/22/2009US20090264467 Agents and crystals for improving excretory potency of urinary bladder
10/22/2009US20090264459 Organic Compounds
10/22/2009US20090264455 Androgen Receptor Modulator Compounds and Methods
10/22/2009US20090264446 Condensed Pyridines as Kinase Inhibitors
10/22/2009US20090264442 Pyrazole derivatives as sigma receptor inhibitors
10/22/2009US20090264435 Novel Aryl- and Heteroarylpiperazines
10/22/2009US20090264425 Chemical compounds
10/22/2009US20090264424 Vanilloid receptor ligands and their use in treatments
10/22/2009US20090264423 Serine-threonine protein kinase and parp modulators
10/22/2009US20090264415 Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
10/22/2009US20090264414 Amide Derivatives and Pharmaceutical Use Thereof
10/22/2009US20090264410 Therapeutic compounds and uses thereof
10/22/2009US20090264405 Cetp Inhibitors
10/22/2009US20090264399 Heterocyclic janus kinase 3 inhibitors
1 ... 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 ... 646